PTPN6 and prostate adenocarcinoma: Among them, the significant decrease in the promoter methylation levels of ptpn6 was observed in tissues of 11 tumors, including BLCA, BRCA, CESC, HNSC, KIRC, KIRP, LUAD, LUSC, prostate adenocarcinoma (PRAD), TGCT and UCEC, compared to normal tissues (Fig. 9).